July 2025 in “Nano Research” Nanotechnology can improve tissue healing by controlling immune responses.
January 2025 in “Dermatology Research and Practice” Higher activity in lichen planopilaris is linked to certain immune and tissue genes.
June 2020 in “Journal of Investigative Dermatology” The symposium highlighted the importance of genetics in understanding and treating complex skin diseases.
May 2026 in “Journal of Neurosciences in Rural Practice” Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
30 citations
,
April 2023 in “Indian Journal of Ophthalmology” New treatments using advanced technology aim to improve dry eye disease care.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
20 citations
,
January 2023 in “Frontiers in Immunology” Skin-associated adipocytes help protect the skin from infections by supporting its immune barrier.
5 citations
,
June 2024 in “Developmental Cell” Activating TRPV1 can boost hair growth by involving neurons, macrophages, and fibroblasts.
227 citations
,
April 2020 in “Cell” More precise, personalized therapies are needed for autoimmune diseases.
22 citations
,
June 2024 in “Cell” Understanding tissue self-organization can improve treatments for diseases and advance regenerative medicine.
9 citations
,
April 2024 in “Heliyon” Probiotics may help with hair growth and dandruff, but more research is needed.
Isotretinoin effectively improved severe pityriasis rubra pilaris with complications.
9 citations
,
June 2023 in “Cells” Certain natural and synthetic compounds may help treat inflammatory skin diseases by targeting a specific signaling pathway.
Iron deficiency worsens inflammatory skin diseases by disrupting iron balance and increasing inflammation.
47 citations
,
March 2022 in “Frontiers in cellular and infection microbiology” Changes in skin microbes play a role in some skin diseases and could lead to new treatments.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
23 citations
,
August 2018 in “Biochimica and biophysica acta. Molecular and cell biology of lipids” Different sPLA2 enzymes affect immunity, skin and hair health, reproduction, and may be potential targets for therapy.
100 citations
,
August 2022 in “Microbial Cell Factories” Balancing skin microbiota is crucial for healthy skin and treating skin diseases.
22 citations
,
April 2021 in “Human Cell” MicroRNAs may help diagnose and treat hair loss disorders.
55 citations
,
November 2019 in “Cellular and Molecular Gastroenterology and Hepatology” Biotin may help treat inflammatory bowel disease by reducing inflammation and improving gut health.
22 citations
,
April 2020 in “Frontiers in Cellular and Infection Microbiology” Alopecia areata may be linked to scalp microbiome differences, suggesting potential treatments with prebiotics, probiotics, and postbiotics.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
26 citations
,
June 2020 in “The Journal of Allergy and Clinical Immunology In Practice” A patient developed a severe skin reaction and died after taking hydroxychloroquine for COVID-19.
January 2018 in “Springer eBooks” PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
April 2018 in “Journal of Investigative Dermatology”
28 citations
,
February 2010 in “British journal of dermatology/British journal of dermatology, Supplement” WNT10A mutations cause varied symptoms in patients with odonto-onycho-dermal dysplasia.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
October 2021 in “Dermatology Reports” Higher IL-17A levels indicate more severe alopecia areata.
January 2019 in “Springer eBooks” Acne is linked to inflammation and insulin resistance, and is associated with various syndromes that require different treatments.